KURA — Kura Oncology, Inc.

Kura Oncology Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Product Revenue: $5.8 million from Comzifty sales, marking the first full quarter of launch and exceeding expectations.
• Collaboration Revenue: $12.5 million from the Kyowa Kirin partnership, down from $14.1 million year-over-year.
• Research and Development Expenses: Increased to $65.3 million from $56 million, driven by ziftomenib combination trials.
• Selling, General and Administrative Expenses: Rose to $31.6 million from $22.8 million, attributed to the commercial launch of Comzifty.
• Net Loss: $73.3 million, compared to a net loss of $57.4 million in Q1 2025.
• Cash Position: As of March 31, 2026, Kura had $580.8 million in cash and equivalents, down from $667.2 million at year-end 2025.

2. Strategic Updates and Business Highlights:

• Comzifty Launch: Strong initial uptake with 85 new patient starts and nearly 160 total prescriptions across 60 activated accounts. Physicians are increasingly differentiating Comzifty based on its efficacy, safety, and convenient dosing.
• Clinical Programs: Phase 3 programs are progressing ahead of schedule, with strong enrollment in the COMMODORE-17 trial. Upcoming data readouts are anticipated from multiple combination studies, reinforcing the potential of ziftomenib as a backbone therapy in AML.
• Pipeline Expansion: Continued exploration of darlafarnib in combination therapies, with promising data expected for KRAS-mutated solid tumors.

3. Forward Guidance and Outlook:

• Collaboration Revenue Guidance: Maintained at $45 million to $55 million for 2026, with expectations of $90 million to $110 million for 2027 and 2028.
• Clinical Milestones: Anticipated data readouts over the next 12 to 24 months that could solidify Kura's leadership in the menin inhibitor class.

4. Bad News, Challenges, or Points of Concern:

• Increased Losses: The net loss widened compared to the previous year, raising concerns about the sustainability of current spending levels.
• Revenue Dependence: The company is heavily reliant on Comzifty's performance and the success of its clinical trials to drive future revenue.
• Competitive Landscape: As a second-to-market player in the menin inhibitor space, Kura faces pressure to establish a strong market presence against established competitors.

5. Notable Q&A Insights:

• Duration of Treatment: Initial expectations for treatment duration with Comzifty are around six months, but further tracking is needed for clarity.
• Combination Use: Approximately 40% of patients are being treated with Comzifty in combination with other therapies, indicating early physician confidence in its profile.
• Switching from Other Inhibitors: Physicians are beginning to switch patients from other menin inhibitors to Comzifty, although this is not expected to be a major trend compared to new patient starts.
• Market Positioning: Kura aims to capture a leading market share in the NPM1 segment, with a goal of exceeding 51% of new patient starts.

Overall, Kura Oncology is positioned at a critical juncture with a promising product launch and a robust pipeline, though it must navigate financial losses and competitive pressures.